多西紫杉醇联合顺铂治疗晚期复发鼻咽癌

Docetaxel Combined with Cisplatin in the Treatment of Advanced and Recurrent Nasopharyngeal Carcinoma

目的:评价多西他赛(DOC)联合顺铂(DDP)治疗复发、转移晚期鼻咽癌的疗效及其不良反应。方法:诊断明确的转移、治疗后复发的晚期鼻咽癌且对PF方案耐药的患者21例;第1天静脉滴注多西他赛75mg/m2,顺铂30mg/m2第(1~3)天静滴,21天为一周期所有患者均治疗2周期,观察不良反应并评价化疗疗效。结果:CR 1例(4.76%),PR 13例(57.14%),SD 5例(23.81%),PD 2例(9.52%)。总有效率66.67%。最常见不良反应是反应骨髓抑制的Ⅲ~Ⅳ度粒细胞减少(76.2%)和Ⅱ~Ⅲ度血小板减少(47.6)。其余毒副反应则可以耐受。结论:DOC联合DDP对复发、转移晚期鼻咽癌的疗效肯定,患者多能耐受其不良反应,此化疗运用于临床可行。

Objective：To evaluate docetaxel （DOC） combined with cisplatin （DDP） and its efficacy in treatment of recurrent, metastatic advanced nasopharyngeal carcinoma.Methods：Diagnosis of metastasis,21 cases of patients with advanced nasopharyngeal carcinoma recurrence and scheme of PF resistance after treatment method;first days of intravenous infusion of docetaxel and cisplatin 75mg/m2, 30mg/m2 days （1~3） intravenous drip, 21 days for a cycle of all patients were treated for 2 cycles,observe the adverse reaction and evaluation of treatment efficacy.Results：CR 1 cases （4.76%）,PR 13 cases （57.14%）,SD 5 cases （23.81%）, 2 cases of PD （9.52%）. The total efficiency of 66.67%.The most common adverse reaction is bone marrow suppression of grade 3-4 neutropenia（76.2%） and II^III thrombocytopenia（47.6）.The toxic and side reaction can be tolerated. The curative effect of advanced nasopharyngeal carcinoma. Conclusion：DOC combined with DDP on recurrence, metastasis, patients can tolerate the adverse reaction of chemotherapy, which are applied to the clinical feasibility, worthy of further research and Application.